Type 2 Diabetes

A follow-up to an earlier episode, this episode features a deep dive into the hosts experience with the Dexcom Stelo sensor.

In this episode, hosts discuss availability of the Abbott Lingo CGM and Embecta’s announcement of FDA clearance for their tubeless patch pump with a 300-unit insulin reservoir.

The endocrinology month in review for August 2024 spotlights 6 pieces of major pipeline news or regulatory announcements as well as multiple episodes of Diabetes Dialogue.

A meta-analysis shows GLP-1 RAs and SGLT2 inhibitors offer distinct cardiovascular and kidney benefits in type 2 diabetes.

Rahul Aggarwal, MD, discusses the findings of a SCORED analysis examining sotagliflozin's effects based on diabetes duration.

Michigan Medicine and U-M research finds a bidirectional link between mental health disorders and chronic diabetes complications, urging comprehensive screenings.

In this episode, hosts discuss the implications of Dexcom announcing availability of their Stelo sensor and the FDA clearance of the Omnipod 5 for type 2 diabetes.

FDA expands Omnipod 5 AID system for type 2 diabetes, marking the first AID system approved for both type 1 and type 2 diabetes management.

Dexcom's Stelo, the first OTC glucose sensor, launches in the US on August 26, 2024, offering 15-day wear and HSA/FSA eligibility for as low as $89.99 per 2-pack.

A new study significantly demonstrated semaglutide, but not liraglutide, is associated with suicidal ideation.

This episode focuses on sotagliflozin in type 1 diabetes and other highlights from the ADCES 2024 annual meeting.

In this episode, hosts react to the announced CMS list prices for the first 10 drugs chosen for negotiation as part of the Inflation Reduction Act.

A new analysis suggests HbA1c may be more informative to fatty liver disease severity than BMI, and should be included in screenings.

The first of 2 episodes on ADCES 2024, this episode focuses on sessions and presentations hosts Isaacs and Bellini participated in during the meeting.

A new real-world study suggests tirzepatide provides greater reductions in mortality, cardiovascular risk, and kidney events than GLP-1 receptor agonists in type 2 diabetes.

In this episode, hosts take a break from the ADCES meeting to discuss the latest news from Medtronic related to their Simplera CGM and their partnership with Abbott.

Treatment with GLP-1 RAs led to improvements in weight loss, liver function tests, and liver fat in patients with diabetes and MASLD, with hepatic improvements independent of weight loss.

FDA approval for the Simplera™ continuous glucose monitor marks the company's first disposable, all-in-one CGM half the size of previous offerings.

The July 2024 endocrinology month in review recaps a pair of regulatory updates, multiple studies on incretin therapies, and the most recent episodes of our flagship diabetes podcast, Diabetes Dialogue.

New study finds semaglutide may reduce smoking urge in type 2 diabetes patients, decreasing tobacco use disorder medical encounters by up to 32%.

An analysis using records from 40 million US patients highlights the surge in new GLP-1 receptor agonist use, with semaglutide dominating new prescriptions since 2020.

A study found individuals with type 2 diabetes who received less than 7 hours of sleep had 2.6 increased odds of microvascular disease.

In this episode, John Buse, MD, PhD, discusses the background, expected prevalence, reaction to results, and the importance of the second part of the CATALYST trial.

Neuen explains the cardiovascular and kidney benefits of combining SGLT2 inhibitors and GLP-1 receptor agonists in diabetes and the future of combination therapy.

The CRL cites requests related to the manufacturing process and the type 1 diabetes indication before the application review can be completed.